Biomarkers of Response to Epidermal Growth Factor Receptor Inhibitors in Non–Small-Cell Lung Cancer Working Group: Standardization for Use in the Clinical Trial Setting Ovarian carcinogenesis, as in ...
Perhaps PD-1 inhibitors just aren’t for ovarian cancer after all. Days after Merck & Co. posted a disappointing result on patient survival from its PD-1/PARP combination of Keytruda and Lynparza in ...
Merck’s Keytruda, with more than 40 approved indications, hasn’t yet been able to crack specifically into ovarian cancer. But with promising early results from a phase 3 study in certain patients, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback